Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

— Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — "We are excited for the focused expansion of KB-0742 in platinum-resistant HGSOC. KB-0742 has to date provided prolonged stable disease of over 300 days in one of my platinum-resistant HGSOC patients," said Howard "Skip" A. Burris M.D., president of Sarah Cannon Research Institute (SCRI). "HGSOC patients have limited treatment options after progressing on platinum therapy and KB-0742 brings new possibilities to those battl ...